Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORP003
MIFTS: 54

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Oropharynx Cancer

About this section

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 12 15 17
Oropharyngeal Cancer 12 36 54 15
Malignant Neoplasm of Oropharynx 12 71 32
Oropharyngeal Carcinoma 12 71
Primary Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Neoplasm of Junctional Region of Oropharynx 12
Malignant Neoplasm of Posterior Wall of Oropharynx 12
Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Tumor of Posterior Wall of Oropharynx 12
Malignant Tumour of Mesopharynx 12
Malignant Oropharyngeal Tumor 12
Malignant Tumor of Oropharynx 12
Oropharyngeal Cancer, Adult 52
Cancer of the Oropharynx 52

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8557
KEGG 36 H01559
NCIt 49 C7398
SNOMED-CT 67 93933005 93971002
UMLS 71 C0153382 C0153388 C0153389 more
Sources

Summaries for Oropharynx Cancer

About this section
KEGG : 36 Oropharyngeal cancer is a generic term that includes tumors arising within the anatomic confines of the posterior pharyngeal wall, soft palate, tonsillar region and posterior one-third (base) of the tongue. The vast majority of these tumors (>95%) includes squamous cell carcinomas of mucosal origin. Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally categorized as head and neck squamous cell carcinoma (HNSCC). High-risk human papillomavirus (HR-HPV) is now recognised as a causative agent in a subset of OPSCCs. HPV-driven OPSCC and tobacco- and alcohol-related OPSCC are biologically distinct entities. In the former, p53 and pRb are both inactivated at the protein level by, respectively, E6 and E7 viral oncoproteins. The majority of HPV-negative tumors, instead, harbor mutations in the TP53 gene, an increased epidermal growth factor receptor (EGFR) gene copy number and higher EGFR expression by immunohistochemistry (IHC).

MalaCards based summary : Oropharynx Cancer, also known as oropharyngeal cancer, is related to oral cancer and hypopharynx cancer. An important gene associated with Oropharynx Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs sodium fluoride and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include the, breast and tongue, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Disease Ontology : 12 A pharynx cancer that is located in the oropharynx.

Wikipedia : 74 Oropharyngeal cancer (OPC) is a disease in which abnormal cells with the potential to both grow locally... more...

Sources

Related Diseases for Oropharynx Cancer

About this section

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 oral cancer 31.0 TP53 EGFR CDKN2A ADH1C
2 hypopharynx cancer 30.9 TP53 MMP8 EGFR CDKN2A
3 nasopharyngeal carcinoma 30.9 TP53 MIR9-1 ERBB2 EGFR CDKN2A
4 tongue cancer 30.8 TP53 MMP8 EGFR CDKN2A
5 anogenital venereal wart 30.8 TP53 H2AC18 GP5 CDKN2A
6 cervix uteri carcinoma in situ 30.8 TP53 GP5 CDKN2A
7 anus cancer 30.8 TP53 KIT H2AC18 GP5 EGFR CDKN2A
8 cervical cancer 30.6 TYMP TP53 MIR9-1 ERBB2 EGFR CDKN2A
9 tonsil squamous cell carcinoma 30.6 MIR193B CDKN2A
10 exanthem 30.6 KIT H2AC18 ERBB2 EGFR
11 tongue disease 30.5 TP53 MMP8 EGFR CDKN2A
12 esophagitis 30.5 TP53 EGFR CDKN2A
13 skin squamous cell carcinoma 30.5 TP53 KIT EGFR CDKN2A
14 small cell carcinoma 30.5 TP53 KIT EGFR CDKN2A
15 cervical squamous cell carcinoma 30.4 TYMP TP53 EGFR CDKN2A
16 squamous cell carcinoma, head and neck 30.4 TYMP TP53 MMP8 MIR9-1 H2AC18 ERBB2
17 in situ carcinoma 30.3 TP53 H2AC18 ERBB2 EGFR CDKN2A
18 ovarian disease 30.1 TP53 KIT H2AC18 ERBB2 EGFR CDKN2A
19 esophageal cancer 30.0 TYMP TP53 MIR9-1 ERBB2 EGFR CDKN2A
20 suppression of tumorigenicity 12 30.0 TP53 SERPINA3 KIT H2AC18 ERBB2 EGFR
21 meningioma, familial 30.0 TP53 SERPINA3 KIT H2AC18 ERBB2 EGFR
22 leukemia, acute myeloid 29.9 TP53 SERPINA3 MIR9-1 KIT H2AC18 ERBB2
23 adenoid cystic carcinoma 29.7 TP53 SERPINA3 NFIB MYBL1 KIT ERBB2
24 pharynx cancer 29.7 TP53 SERPINA3 NFIB MMP8 MIR9-1 MIR193B
25 keratosis 29.6 TP53 EGFR CDKN2A
26 oral cavity cancer 29.6 TP53 SERPINA3 MMP8 MIR9-1 MIR193B MAML2
27 tonsil cancer 29.5 TP53 SERPINA3 NFIB MYBL1 MIR193B MAML2
28 lung cancer susceptibility 3 29.4 TYMP TP53 SERPINA3 MIR9-1 MIR193B KIT
29 obsolete: hiv-related oropharyngeal cancer 12.4
30 cutaneous telangiectasia and cancer syndrome, familial 12.2
31 vulvar intraepithelial neoplasia 10.7 TP53 CDKN2A
32 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
33 parotid gland adenoid cystic carcinoma 10.7 ERBB2 CDKN2A
34 anus basaloid carcinoma 10.7 KIT CDKN2A
35 cervical adenoid cystic carcinoma 10.7 NFIB KIT CDKN2A
36 acinar cell cystadenocarcinoma 10.7 SERPINA3 ACCS
37 trachea adenoid cystic carcinoma 10.7 KIT ACCS
38 ovarian seromucinous carcinoma 10.7 TP53 CDKN2A
39 supraglottis cancer 10.7 MMP8 EGFR CDKN2A
40 esophagus verrucous carcinoma 10.7 TP53 EGFR CDKN2A
41 verrucous carcinoma 10.7 TP53 EGFR CDKN2A
42 lacrimal system cancer 10.7 NFIB MAML2 ACCS
43 lacrimal gland mucoepidermoid carcinoma 10.7 MAML2 CRTC1
44 hyperplastic polyposis syndrome 10.7 TP53 APC
45 heart leiomyosarcoma 10.6 KIT CDKN2A
46 bone squamous cell carcinoma 10.6 TP53 EGFR CDKN2A
47 spitz nevus 10.6 TP53 CDKN2A
48 lacrimal gland adenocarcinoma 10.6 NFIB ACCS
49 fibrosarcoma of bone 10.6 SERPINA3 KIT CDKN2A
50 esophageal basaloid squamous cell carcinoma 10.6 TP53 EGFR

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer
Sources

Symptoms & Phenotypes for Oropharynx Cancer

About this section

MGI Mouse Phenotypes related to Oropharynx Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ADH1C APC CDKN2A CRTC1 EGFR ERBB2
2 endocrine/exocrine gland MP:0005379 9.91 APC CDKN2A CRTC1 EGFR ERBB2 KIT
3 neoplasm MP:0002006 9.5 APC CDKN2A EGFR ERBB2 KIT MMP8
4 pigmentation MP:0001186 9.02 APC CDKN2A EGFR KIT TP53
Sources

Drugs & Therapeutics for Oropharynx Cancer

About this section

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 sodium fluoride Approved Phase 4 7681-49-4
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
5 Listerine Phase 4
6 Cariostatic Agents Phase 4
7 Psychotropic Drugs Phase 4
8 Central Nervous System Stimulants Phase 4
9 Cholinergic Agents Phase 4
10 Nicotinic Agonists Phase 4
11 Liver Extracts Phase 4
12 Dopamine Uptake Inhibitors Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Dopamine Agents Phase 4
15 Antidepressive Agents Phase 4
16 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
17 Mitomycins Phase 4
18
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
19
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
20
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
21
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
22
nivolumab Approved Phase 3 946414-94-4
23
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
24
Durvalumab Approved, Investigational Phase 3 1428935-60-7
25
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
26
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
27
Icodextrin Approved, Investigational Phase 3 337376-15-5
28 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
29
Lobeline Investigational Phase 2, Phase 3 90-69-7
30
Tremelimumab Investigational Phase 3 745013-59-6
31 Tranquilizing Agents Phase 3
32 Anti-Anxiety Agents Phase 3
33 Anticonvulsants Phase 3
34 Antimanic Agents Phase 3
35 Excitatory Amino Acid Antagonists Phase 3
36 Excitatory Amino Acids Phase 3
37 Respiratory System Agents Phase 2, Phase 3
38 Muscarinic Agonists Phase 2, Phase 3
39 Antibodies, Monoclonal Phase 2, Phase 3
40 Immunoglobulin G Phase 2, Phase 3
41 Pharmaceutical Solutions Phase 3
42
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
43
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
44
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
45
Indinavir Approved Phase 2 150378-17-9 5362440
46
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
47
Trioxsalen Approved Phase 2 3902-71-4 5585
48
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
49
Zinc Approved, Investigational Phase 2 7440-66-6 32051
50
Zinc oxide Approved Phase 2 1314-13-2

Interventional clinical trials:

(show top 50) (show all 232)
# Name Status NCT ID Phase Drugs
1 Essential Oils With and Without Alcohol: in Vivo Antibacterial Effect Unknown status NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
2 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer Recruiting NCT03691441 Phase 4 Chemotherapy
5 Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
6 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
7 Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy: a Prospective, Randomized, Double-blind Versus Placebo Study Unknown status NCT02618993 Phase 3
8 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Unknown status NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
9 Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection (ESSAN): a Double-blinded, Randomized Control Trial Unknown status NCT02268344 Phase 3
10 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
11 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
12 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
13 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
14 A Pilot Study to Compare the Nicotine Lozenge and Tobacco-Free Snuff for Smokeless Tobacco Reduction Completed NCT01018394 Phase 2, Phase 3 nicotine lozenges;tobacco-free snuff
15 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
16 DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin
17 A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA Recruiting NCT03811015 Phase 2, Phase 3 Cisplatin
18 Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer Recruiting NCT04116047 Phase 3 Cisplatin;Durvalumab
19 Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy Recruiting NCT04019548 Phase 3 Cisplatin injection
20 A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck Recruiting NCT03576417 Phase 3 Cisplatin;Nivolumab
21 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Recruiting NCT03952585 Phase 2, Phase 3 Cisplatin
22 A Phase II/III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer Recruiting NCT02215265 Phase 3 Cisplatin
23 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
24 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Recruiting NCT01893307 Phase 2, Phase 3
25 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
26 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Active, not recruiting NCT01302834 Phase 3 cisplatin
27 Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia Active, not recruiting NCT01874587 Phase 3
28 The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer Active, not recruiting NCT01706939 Phase 3 Carboplatin
29 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
30 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
31 Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia Active, not recruiting NCT01266044 Phase 3
32 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
33 A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, With and Without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients With Advanced Oropharyngeal Squamous Cell Cancer Terminated NCT00268372 Phase 3 cisplatin;docetaxel;5-fluorouracil
34 Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT00004227 Phase 3
35 Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) Trial for Oropharynx Malignancy Terminated NCT01687413 Phase 3 Cisplatin
36 Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
37 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
38 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
39 Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer Unknown status NCT01440270 Phase 2 Neo-adjuvant Erbitux-based chemotherapy
40 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
41 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
42 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
43 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
44 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
45 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
46 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Completed NCT02159703 Phase 2
47 Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer Completed NCT00006360 Phase 1, Phase 2 radioprotection
48 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
49 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer Completed NCT01032928 Phase 2
50 Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) Completed NCT01733797 Phase 2

Search NIH Clinical Center for Oropharynx Cancer

Sources

Genetic Tests for Oropharynx Cancer

About this section
Sources

Anatomical Context for Oropharynx Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Oropharynx Cancer:

19
The

MalaCards organs/tissues related to Oropharynx Cancer:

40
Breast, Tongue, Lymph Node, Tonsil, Lung, Testes, T Cells
Sources

Publications for Oropharynx Cancer

About this section

Articles related to Oropharynx Cancer:

(show top 50) (show all 2756)
# Title Authors PMID Year
1
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. 54 61
17378915 2007
2
Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. 54 61
9050916 1997
3
Stability analysis of CT radiomic features with respect to segmentation variation in oropharyngeal cancer. 61
31886423 2020
4
Factors associated with severe oral mucositis and candidiasis in patients undergoing radiotherapy for oral and oropharyngeal carcinomas: a retrospective multicenter study of 326 patients. 61
31177394 2020
5
How Can Dental Practitioners Join the Fight Against HPV-Associated Oropharyngeal Cancer? 61
32017590 2020
6
Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. 61
32017652 2020
7
Trends in Reporting of Swallowing Outcomes in Oropharyngeal Cancer Studies: A Systematic Review. 61
30847548 2020
8
Establishment of epigenetic markers to predict irradiation efficacy against oropharyngeal cancer. 61
32012407 2020
9
From presumed benign neck masses to delayed recognition of human papillomavirus-positive oropharyngeal cancer. 61
30950517 2020
10
Impact of active smoking on outcomes in HPV+ oropharyngeal cancer. 61
31769100 2020
11
Potential therapeutic implications of the new tumor, node, metastasis staging system for human papillomavirus-mediated oropharyngeal cancer. 61
32022732 2020
12
Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. 61
31304592 2020
13
Automatic configuration of the reference point method for fully automated multi-objective treatment planning applied to oropharyngeal cancer. 61
32017144 2020
14
Evaluating the impact of smoking on disease-specific survival outcomes in patients with human papillomavirus-associated oropharyngeal cancer treated with transoral robotic surgery. 61
32032441 2020
15
TORPEdO - A Phase III Trial of Intensity-modulated Proton Beam Therapy Versus Intensity-modulated Radiotherapy for Multi-toxicity Reduction in Oropharyngeal Cancer. 61
31604604 2020
16
Clinical Value of Fused PET/MRI for Surgical Planning in Patients With Oral/Oropharyngeal Carcinoma. 61
30897225 2020
17
Quantitative Oral HPV16 and HPV18 Detection in Persons Attending Dental Clinics. 61
31804297 2020
18
Predictors and Prevalence of Nodal Disease in Salvage Oropharyngectomy. 61
31538289 2020
19
Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers. 61
31816512 2020
20
Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age. 61
31881446 2020
21
Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer. 61
30919470 2020
22
Influence of remoteness of residence on timeliness of diagnosis and treatment of oral cavity and oropharynx cancer: A retrospective cohort study. 61
32037663 2020
23
Neuropeptide receptor genes GHSR and NMUR1 are candidate epigenetic biomarkers and predictors for surgically treated patients with oropharyngeal cancer. 61
31974445 2020
24
Quantitative Bias Analysis of misclassification in case-control studies: an example with Human Papillomavirus and Oropharyngeal Cancer. 61
32031348 2020
25
Speech handicap index: cross-cultural adaptation and validation in European Portuguese speakers with oral and oropharyngeal cancer. 61
31918604 2020
26
The role of multidisciplinary decision making in oropharyngeal cancer: do we follow guidelines and are treatment decisions being implemented? 61
31915919 2020
27
Do not de-escalate oncology care in oropharyngeal cancer routinely. 61
31512784 2020
28
Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". 61
31906998 2020
29
CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. 61
31937831 2020
30
Bilateral vertebral collections in a patient with "end-stage" osteoradionecrosis after radiotherapy for oropharyngeal cancer. 61
31767134 2020
31
Return to Work in Survivors of Human Papillomavirus-Associated Oropharyngeal Cancer: An Australian Experience. 61
31521718 2020
32
Predictors of swallow function after transoral surgery for locally advanced oropharyngeal cancer. 61
30957243 2020
33
Reply to "Do not de-escalate oncology care in oropharyngeal cancer routinely". 61
31512788 2020
34
Effects of oral and oropharyngeal cancer on speech intelligibility using acoustic analysis: Systematic review. 61
31571334 2020
35
Mortality due to oral and oropharyngeal cancer in Uruguay from 1997 to 2014. 61
31800875 2020
36
Dietary glycaemic index, glycaemic load and head and neck cancer risk: a pooled analysis in an international consortium. 61
31929514 2020
37
Global trends in oral and pharyngeal cancer incidence and mortality. 61
31953840 2020
38
Molecular mechanisms of tobacco induced oral and oropharyngeal cancer: Results of a tissue microarray and immunohistochemistry-based study from a tertiary cancer center in India. 61
32031115 2020
39
STOP HPV study protocol: a nationwide case-control study of the association between oropharyngeal cancer and human papillomavirus (HPV) infection in Brazil. 61
32001492 2020
40
Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. 61
31794928 2020
41
A Practical Risk Measure for Identification of Adults With Oncogenic Oral Human Papillomavirus: Potential Use in Primary Care. 61
31914181 2020
42
Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. 61
31431373 2020
43
Impact of insurance on survival in patients < 65 with head & neck cancer treated with radiotherapy. 61
31661188 2020
44
Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. 61
31037378 2020
45
Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. 61
31930488 2020
46
Surgical rescue for persistent head and neck cancer after first-line treatment. 61
31982945 2020
47
Lymphopenia during radiotherapy in patients with oropharyngeal cancer. 61
31931292 2020
48
Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments? 61
31536144 2020
49
Prostanoid receptor genes confer poor prognosis in head and neck squamous cell carcinoma via epigenetic inactivation. 61
31969157 2020
50
Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls. 61
31943172 2020
Sources

Variations for Oropharynx Cancer

About this section

Cosmic variations for Oropharynx Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90409508 upper aerodigestive tract,oropharynx,carcinoma,squamous cell carcinoma c.3734G>A p.R1245Q 16:2081718-2081718 0
Sources

Expression for Oropharynx Cancer

About this section
Search GEO for disease gene expression data for Oropharynx Cancer.
Sources

Pathways for Oropharynx Cancer

About this section

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 36
Show member pathways
 12.82 TP53 MAML2 KIT ERBB2 EGFR APC
2
Endometrial cancer 36
Show member pathways
 12.7 TP53 KIT ERBB2 EGFR CDKN2A APC
3
Pathways in cancer 36
12.66 TP53 KIT ERBB2 EGFR CDKN2A APC
4
Gastric cancer 36
Show member pathways
 12.47 TP53 KIT ERBB2 EGFR CDKN2A APC
5
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.24 TYMP KIT ERBB2 EGFR APC
6
DNA Damage Response (only ATM dependent) 1
11.79 TP53 ERBB2 CDKN2A APC
7
Glioblastoma Multiforme 63
11.71 TP53 EGFR CDKN2A APC
8
MicroRNAs in cancer 36
11.66 TP53 MIR9-1 MIR193B ERBB2 EGFR CDKN2A
9
Platinum drug resistance 36
11.58 TP53 ERBB2 CDKN2A
10
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.53 ERBB2 EGFR APC
11
Central carbon metabolism in cancer 36
11.4 TP53 KIT ERBB2 EGFR
12
Photodynamic therapy-induced AP-1 survival signaling. 1
11.38 TP53 EGFR CDKN2A
13
Pathways Affected in Adenoid Cystic Carcinoma 1
11.28 TP53 NFIB MYBL1 ERBB2
14
Bladder cancer 36 1
11.22 TYMP TP53 ERBB2 EGFR CDKN2A
15
Extracellular vesicle-mediated signaling in recipient cells 1
11.06 ERBB2 EGFR APC
Sources

GO Terms for Oropharynx Cancer

About this section

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 TP53 NFIB MYBL1 MAML2 EGFR CRTC1
2 positive regulation of gene expression GO:0010628 9.77 TP53 MMP8 KIT ERBB2 CDKN2A
3 negative regulation of cell proliferation GO:0008285 9.72 TP53 NFIB MIR9-1 CDKN2A APC
4 replicative senescence GO:0090399 9.51 TP53 CDKN2A
5 positive regulation of pseudopodium assembly GO:0031274 9.49 KIT APC
6 tongue development GO:0043586 9.48 KIT EGFR
7 regulation of microtubule-based process GO:0032886 9.46 ERBB2 APC
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 EGFR
9 somatic stem cell division GO:0048103 9.4 KIT CDKN2A
10 positive regulation of MAP kinase activity GO:0043406 9.33 KIT ERBB2 EGFR
11 negative regulation of ERBB signaling pathway GO:1901185 8.96 ERBB2 EGFR
12 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 ERBB2 CDKN2A

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 TP53 ERBB2 EGFR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 KIT ERBB2 EGFR
Sources

Sources for Oropharynx Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....